Coloplast A/S (OTCMKTS:CLPBY) Posts Quarterly Earnings Results, Misses Estimates By $0.01 EPS

Coloplast A/S (OTCMKTS:CLPBY) posted its quarterly earnings results on Tuesday. The company reported $0.07 earnings per share (EPS) for the quarter, missing the consensus estimate of $0.08 by ($0.01), Zacks reports. Coloplast A/S had a net margin of 18.69% and a return on equity of 30.19%. Coloplast A/S updated its FY 2025 guidance to EPS.

Coloplast A/S Stock Performance

OTCMKTS:CLPBY opened at $11.18 on Thursday. The company has a current ratio of 1.02, a quick ratio of 0.66 and a debt-to-equity ratio of 0.92. The business’s 50-day simple moving average is $11.43 and its 200-day simple moving average is $12.56. Coloplast A/S has a fifty-two week low of $10.63 and a fifty-two week high of $14.34.

Coloplast A/S Increases Dividend

The firm also recently declared a dividend, which was paid on Friday, December 20th. Shareholders of record on Monday, December 9th were issued a $0.2435 dividend. This is an increase from Coloplast A/S’s previous dividend of $0.05. The ex-dividend date was Monday, December 9th. Coloplast A/S’s dividend payout ratio is 93.94%.

Analysts Set New Price Targets

Several equities analysts have recently issued reports on the company. UBS Group upgraded Coloplast A/S from a “strong sell” rating to a “hold” rating in a research report on Wednesday, December 11th. Hsbc Global Res raised shares of Coloplast A/S from a “moderate sell” rating to a “hold” rating in a research note on Monday, November 18th. Finally, Sanford C. Bernstein upgraded shares of Coloplast A/S from a “hold” rating to a “strong-buy” rating in a report on Tuesday, January 28th.

About Coloplast A/S

Coloplast A/S engages in the development and sale of intimate healthcare products and services in Denmark, the United States, the United Kingdom, France, and internationally. The company operates through Chronic Care, Continence Care, Voice and Respiratory Care, Interventional Urology, and Advanced Wound Care segments.